A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

NCT05323253 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Squamous Cell Carcinoma

Interventions

DEVICE: DaRT seeds

Sponsor

Alpha Tau Medical LTD.